PE-Backed WuXi Biologics’ $510M Hong Kong IPO Cheered By Investors

WuXi Biologics (Cayman) Inc., a Chinese contract drug manufacturer whose parent company is controlled by a group of leading private equity firms, has seen its share price soar after completing a HK$3.98 billion (US$510 million) initial public offering on the Kong Exchange Stock Exchange.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY